MedWatch

Eli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDA

Results from a phase III study with diabetes drug Jardiance are so promising that that the FDA has granted the medication breakthrough designation for fast tracking.

Photo: Mike Blake/REUTERS / X00030

The US Food and Drug Administration (FDA) has designated the drug Jardiance from Eli Lilly and Boehringer Ingelheim the status 'breakthrough,' which fasttracks the application of the substance against a special type of heart failure, Eli Lilly informs in a statement. The FDA further explains the special status with the promising results from a phase III trial with Jardiance in the above indication.

According to Eli Lilly, the study confirms that Jardiance is the first treatment to significantly improve conditions for adults with weakened left ventricle muscles.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs